In this sense, a rigorous follow‐up is recommended for early‐stage melanoma patients with a high Breslow thickness, high serum IL‐4 levels, and low GM‐CSF and DCD levels at the time of diagnosis, given the elevated risk for these patients to develop metastasis during follow‐up. This evidence concerns the gene IL4 and melanoma.